What's Happening?
Delcath Systems, Inc., an interventional oncology company, has announced that its CHOPIN Phase 2 clinical trial has met its primary endpoint. The trial, presented at the 2025 European Society of Medical
Oncology Annual Congress, evaluated the efficacy of Delcath's CHEMOSAT Hepatic Delivery System combined with immune checkpoint inhibitors ipilimumab and nivolumab in treating metastatic uveal melanoma. The trial demonstrated significant improvements in progression-free survival and overall response rates in patients receiving the combination therapy compared to those receiving the hepatic perfusion treatment alone. The combination group showed a one-year progression-free survival rate of 54.7% compared to 15.8% in the PHP group.
Why It's Important?
The successful results of the CHOPIN trial represent a significant advancement in the treatment of metastatic uveal melanoma, a challenging cancer with limited treatment options. The combination of hepatic perfusion and immune checkpoint inhibitors could offer a new therapeutic strategy, potentially improving outcomes for patients with liver-dominant disease. This development may also pave the way for broader applications of the treatment in other cancers with similar characteristics, enhancing the therapeutic landscape for liver cancer patients.
What's Next?
Delcath Systems plans to further investigate the potential of combining hepatic perfusion with immune checkpoint inhibitors in other cancers with liver-dominant disease. The company is also focused on increasing the adoption of its HEPZATO KIT and CHEMOSAT systems, aiming to improve patient outcomes and expand its market presence. A conference call is scheduled to discuss the trial results and future plans, indicating ongoing engagement with the medical community and stakeholders.
